ZA933567B - Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease - Google Patents

Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease

Info

Publication number
ZA933567B
ZA933567B ZA933567A ZA933567A ZA933567B ZA 933567 B ZA933567 B ZA 933567B ZA 933567 A ZA933567 A ZA 933567A ZA 933567 A ZA933567 A ZA 933567A ZA 933567 B ZA933567 B ZA 933567B
Authority
ZA
South Africa
Prior art keywords
fluoroallylamine
fluorophenethyl
alzheimer
disease
treatment
Prior art date
Application number
ZA933567A
Other languages
English (en)
Inventor
Ian A Mcdonald
Michael G Palfreyman
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of ZA933567B publication Critical patent/ZA933567B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA933567A 1992-05-27 1993-05-21 Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease ZA933567B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88867192A 1992-05-27 1992-05-27

Publications (1)

Publication Number Publication Date
ZA933567B true ZA933567B (en) 1993-12-13

Family

ID=25393634

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA933567A ZA933567B (en) 1992-05-27 1993-05-21 Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease

Country Status (15)

Country Link
EP (1) EP0642338B1 (es)
JP (1) JPH07507299A (es)
KR (1) KR950701518A (es)
AT (1) ATE147978T1 (es)
AU (1) AU672401B2 (es)
CA (1) CA2135752C (es)
DE (1) DE69307702T2 (es)
DK (1) DK0642338T3 (es)
ES (1) ES2101311T3 (es)
GR (1) GR3022608T3 (es)
HU (1) HUT72316A (es)
MX (1) MX9303074A (es)
NO (1) NO944524D0 (es)
WO (1) WO1993024120A1 (es)
ZA (1) ZA933567B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684545B2 (en) * 1993-09-24 1997-12-18 Merrell Pharmaceuticals Inc. Transdermal device containing (E)-2-(P-fluorophenethyl)-3-fluoroallylamine for the treatment of Alzheimer's disease
US5599986A (en) * 1994-09-29 1997-02-04 Hoechst Marion Roussel Inc. Process for the preparation of alkali metal salts of diformylamide
US5488188A (en) * 1994-09-29 1996-01-30 Merrell Dow Pharmaceuticals Inc. Process for the preparation of (E)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane, novel processes for preparing an intermediate thereof, and novel intermediates thereof
EP2004166A2 (en) * 2006-03-31 2008-12-24 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR243493A1 (es) * 1987-06-16 1993-08-31 Merrell Dow Pharma Procedimiento para preparar (e)-2-(p-fluorfenetil)-3-fluoralilamina y sus sales farmaceuticamente aceptables, util como inhibidor de mao-b irreversible y activado por enzimas.

Also Published As

Publication number Publication date
HU9403384D0 (en) 1995-02-28
ES2101311T3 (es) 1997-07-01
EP0642338A1 (en) 1995-03-15
DK0642338T3 (da) 1997-02-10
WO1993024120A1 (en) 1993-12-09
CA2135752A1 (en) 1993-12-09
JPH07507299A (ja) 1995-08-10
CA2135752C (en) 1998-07-14
NO944524L (no) 1994-11-25
MX9303074A (es) 1994-01-31
DE69307702T2 (de) 1997-05-28
GR3022608T3 (en) 1997-05-31
HUT72316A (en) 1996-04-29
NO944524D0 (no) 1994-11-25
DE69307702D1 (de) 1997-03-06
KR950701518A (ko) 1995-04-28
ATE147978T1 (de) 1997-02-15
EP0642338B1 (en) 1997-01-22
AU3978293A (en) 1993-12-30
AU672401B2 (en) 1996-10-03

Similar Documents

Publication Publication Date Title
EP0735870A4 (en) USE OF PHOSPHOLIPASE-A2 INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
GR3029670T3 (en) Treatment of macular degeneration.
HK1003978A1 (en) Composition for the treatment of schizophrenia
EP0541686A4 (en) Tachykinin agonists for treatment of alzheimer's disease
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
IL86423A0 (en) Pharmaceutical compositions for the treatment of alzheimer's disease
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
ZA933567B (en) Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
GR3036260T3 (en) Use of olanzapine for the manufacture of a medicament for the treatment of cerebral focal ischemia
FI953725A (fi) Ornitiiniaminotransferaasi-inhibiittorien käyttö lääkeaineen valmistamiseksi Alzheimerin taudin hoitamiseksi
LV5179A3 (lv) Preparats "etoksidins" teju kunga un zarnu slimibu profilaksei un arstesanai
GB9109887D0 (en) Pharmaceutical formulations for the treatment of peripheral vascular diseases
SI0664121T1 (en) Use of raloxifene and its analogs for the manufacture of a medicament for the treatment of atherosclerose and ischaemic heart disease